Imaging procedures such as 1-(2-[18F]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.

Start Date29 Sep 2022

Sponsor / Collaborator

Barbara Ann Karmanos Cancer Institute

[+1]

100 Clinical Results associated with 1-(2-[18F]FLUOROETHYL)-L-Tryptophan

100 Translational Medicine associated with 1-(2-[18F]FLUOROETHYL)-L-Tryptophan

100 Patents (Medical) associated with 1-(2-[18F]FLUOROETHYL)-L-Tryptophan

Literatures (Medical) associated with 1-(2-[18F]FLUOROETHYL)-L-Tryptophan

12 Mar 2015·ACS Medicinal Chemistry LettersQ3 · MEDICINE

N¹-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase

Q3 · MEDICINE

Article

Author: Van den Eynde, Benoit ; Lemaire, Christian ; Laurent, Sophie ; Goldman, Serge ; Henrottin, Jean ; Sapunaric, Frédéric ; Luxen, André ; Plenevaux, Alain ; Zervosen, Astrid

Indoleamine 2,3-dioxygenase (hIDO) is an enzyme that catalyzes the oxidative cleavage of the indole ring of l-tryptophan through the kynurenine pathway, thereby exerting immunosuppressive properties in inflammatory and tumoral tissues. The syntheses of 1-(2-fluoroethyl)-tryptophan (1-FETrp) and 1-((1-(2-fluoroethyl)-1H-1,2,3-triazol-4-yl)methyl)-tryptophan, two N (1)-fluoroalkylated tryptophan derivatives, are described here. In vitro enzymatic assays with these two new potential substrates of hIDO show that 1-FETrp is a good and specific substrate of hIDO. Therefore, its radioactive isotopomer, 1-[(18)F]FETrp, should be a molecule of choice to visualize tumoral and inflammatory tissues and/or to validate new potential inhibitors.

01 Oct 2013·Nuclear Medicine and BiologyQ4 · MEDICINE

Synthesis and biological evaluation of N-(2-[18F]Fluoropropionyl)-L-methionine for tumor imaging

Q4 · MEDICINE

Article

Author: Kong-Zhen Hu ; Shanzhen He ; Hongliang Wang ; Xiaolan Tang ; Tingting Huang ; Xiang Liang ; Ganghua Tang

INTRODUCTIONN-position radiolabeled amino acids, such as N-(2-[(18)F]fluoropropionyl)-L-methionine ([(18)F]FPMET) as a derivative of L-methionine (MET), can potentially serve as a PET tracer for tumor imaging. In the current study, radiosynthesis and biological evaluation of [(18)F]FPMET as a new PET tumor agent are performed.METHODS[(18)F]FPMET was synthesized by reacting 4-nitrophenyl 2-[(18)F]fluoropropionate ([(18)F]NFP) with MET. In vitro competitive inhibition and protein incorporation experiments were performed with Hepa1-6 hepatoma cell lines. The biodistribution of [(18)F]FPMET was determined in S180 fibrosarcoma-bearing mice. PET/CT studies of [(18)F]FPMET were conducted in S180 fibrosarcoma-bearing mice, A549 lung adenocarcinoma-bearing nude mice, and PC-3 prostate cancer-bearing nude mice.RESULTS[(18)F]FPMET was synthesized in 72%± 4% uncorrected radiochemical yield (n=10) from [(18)F]NFP. In vitro experiments showed that [(18)F]FPMET was primarily transported through Na(+)-dependent system A, system ASC, and system B(0,+), and was not incorporated into protein. Biodistribution and PET/CT imaging studies indicated that [(18)F]FPMET could delineate S180 fibrosarcoma, A549 lung adenocarcinoma, and PC-3 prostate cancer.CONCLUSIONAn efficient synthesis of N-position [(18)F]labeled amino acids with a classic [(18)F]NFP prosthetic group is developed. The results support that [(18)F]FPMET seems to be a potential tracer for tumor imaging with PET.

01 Feb 2010·Applied Radiation and Isotopes

Synthesis and evaluation of l-5-(2-[18F]fluoroethoxy)tryptophan as a new PET tracer

Article

Author: Shih-Chen Wu ; Zhe Fu ; Li Huo ; Yonghong Dang ; Ruifen Li ; Shih-Chen Wang

A convenient remote controlled synthesis of a new tryptophan analog, l-5-(2-[(18)F] fluoroethoxy)-tryptophan (5-(18)FEHTP) was described. The radiochemical yield within 65min was about 12-16% without decay correction, the radiochemical purity was over 98%, and 5-(18)FEHTP dissolved in saline was stable over 6h at room temperature. The biodistribution of 5-(18)FEHTP in mice and the high uptake of 5-(18)FEHTP in tumor demonstrated that it is very likely a new PET tracer for tumor imaging.

100 Deals associated with 1-(2-[18F]FLUOROETHYL)-L-Tryptophan

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain metastases	Phase 1	US	Barbara Ann Karmanos Cancer Institute	29 Sep 2022
Breast Cancer	Phase 1	US	Barbara Ann Karmanos Cancer Institute	29 Sep 2022
Glioma	Phase 1	US	Barbara Ann Karmanos Cancer Institute	29 Sep 2022
Neuroendocrine Tumors	Phase 1	US	Barbara Ann Karmanos Cancer Institute	29 Sep 2022
Rectal Cancer	Phase 1	US	Barbara Ann Karmanos Cancer Institute	29 Sep 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

1-(2-[18F]FLUOROETHYL)-L-Tryptophan

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation